These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 36470574)

  • 1. Neurofilament light chain in cerebrospinal fluid as a novel biomarker in evaluating both clinical severity and therapeutic response in Niemann-Pick disease type C1.
    Agrawal N; Farhat NY; Sinaii N; Do AD; Xiao C; Berry-Kravis E; Bianconi S; Masvekar R; Bielekova B; Solomon B; Porter FD
    Genet Med; 2023 Mar; 25(3):100349. PubMed ID: 36470574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated cerebrospinal fluid ubiquitin C-terminal hydrolase-L1 levels correlate with phenotypic severity and therapeutic response in Niemann-Pick disease, type C1.
    Cawley NX; Giddens S; Farhat NM; Luke RA; Scott KEJ; Mohamed HO; Dang Do A; Berry-Kravis E; Cologna SM; Liu F; Porter FD
    Mol Genet Metab; 2023 Nov; 140(3):107656. PubMed ID: 37517328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial.
    Ory DS; Ottinger EA; Farhat NY; King KA; Jiang X; Weissfeld L; Berry-Kravis E; Davidson CD; Bianconi S; Keener LA; Rao R; Soldatos A; Sidhu R; Walters KA; Xu X; Thurm A; Solomon B; Pavan WJ; Machielse BN; Kao M; Silber SA; McKew JC; Brewer CC; Vite CH; Walkley SU; Austin CP; Porter FD
    Lancet; 2017 Oct; 390(10104):1758-1768. PubMed ID: 28803710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial.
    Hastings C; Liu B; Hurst B; Cox GF; Hrynkow S
    Mol Genet Metab; 2022 Dec; 137(4):309-319. PubMed ID: 36279795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal Fluid Calbindin D Concentration as a Biomarker of Cerebellar Disease Progression in Niemann-Pick Type C1 Disease.
    Bradbury A; Bagel J; Sampson M; Farhat N; Ding W; Swain G; Prociuk M; O'Donnell P; Drobatz K; Gurda B; Wassif C; Remaley A; Porter F; Vite C
    J Pharmacol Exp Ther; 2016 Aug; 358(2):254-61. PubMed ID: 27307499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of N-palmitoyl-O-phosphocholineserine for diagnosis and assessment of response to treatment in Niemann-Pick type C disease.
    Sidhu R; Kell P; Dietzen DJ; Farhat NY; Do AND; Porter FD; Berry-Kravis E; Vite CH; Reunert J; Marquardt T; Giugliani R; Lourenço CM; Bodamer O; Wang RY; Plummer E; Schaffer JE; Ory DS; Jiang X
    Mol Genet Metab; 2020 Apr; 129(4):292-302. PubMed ID: 32033912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling.
    Fan M; Sidhu R; Fujiwara H; Tortelli B; Zhang J; Davidson C; Walkley SU; Bagel JH; Vite C; Yanjanin NM; Porter FD; Schaffer JE; Ory DS
    J Lipid Res; 2013 Oct; 54(10):2800-14. PubMed ID: 23881911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microglia activation in Niemann-Pick disease, type C1 is amendable to therapeutic intervention.
    Cougnoux A; Drummond RA; Collar AL; Iben JR; Salman A; Westgarth H; Wassif CA; Cawley NX; Farhat NY; Ozato K; Lionakis MS; Porter FD
    Hum Mol Genet; 2018 Jun; 27(12):2076-2089. PubMed ID: 29617956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Miglustat With Swallowing Outcomes in Niemann-Pick Disease, Type C1.
    Solomon BI; Smith AC; Sinaii N; Farhat N; King MC; Machielse L; Porter FD
    JAMA Neurol; 2020 Dec; 77(12):1564-1568. PubMed ID: 32897301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential Effects of 2-Hydroxypropyl-Cyclodextrins on Lipid Accumulation in
    Hoque S; Kondo Y; Sakata N; Yamada Y; Fukaura M; Higashi T; Motoyama K; Arima H; Higaki K; Hayashi A; Komiya T; Ishitsuka Y; Irie T
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of cerebral spinal fluid protein biomarkers in Niemann-Pick disease, type C1.
    Campbell K; Cawley NX; Luke R; Scott KEJ; Johnson N; Farhat NY; Alexander D; Wassif CA; Li W; Cologna SM; Berry-Kravis E; Do AD; Dale RK; Porter FD
    Biomark Res; 2023 Jan; 11(1):14. PubMed ID: 36721240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accumulation of alkyl-lysophosphatidylcholines in Niemann-Pick disease type C1.
    Mishra S; Kell P; Scherrer D; Dietzen DJ; Vite CH; Berry-Kravis E; Davidson C; Cologna SM; Porter FD; Ory DS; Jiang X
    J Lipid Res; 2024 Aug; 65(8):100600. PubMed ID: 39048052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of a glycinated bile acid biomarker for diagnosis and assessment of response to treatment in Niemann-pick disease type C1.
    Sidhu R; Kell P; Dietzen DJ; Farhat NY; Do AND; Porter FD; Berry-Kravis E; Reunert J; Marquardt T; Giugliani R; Lourenço CM; Wang RY; Movsesyan N; Plummer E; Schaffer JE; Ory DS; Jiang X
    Mol Genet Metab; 2020 Dec; 131(4):405-417. PubMed ID: 33257258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of glutamate neurotoxicity: A novel therapeutic approach for Niemann-Pick disease, type C1.
    Cougnoux A; Yerger JC; Fellmeth M; Serra-Vinardell J; Navid F; Wassif CA; Cawley NX; Porter FD
    Mol Genet Metab; 2021 Dec; 134(4):330-336. PubMed ID: 34802899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term administration of intravenous Trappsol® Cyclo™ (HP-β-CD) results in clinical benefits and stabilization or slowing of disease progression in patients with Niemann-Pick disease type C1: Results of an international 48-week Phase I/II trial.
    Sharma R; Hastings C; Staretz-Chacham O; Raiman J; Paucar M; Spiegel R; Murray B; Hurst B; Liu B; Kjems L; Hrynkow S
    Mol Genet Metab Rep; 2023 Sep; 36():100988. PubMed ID: 37670901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypic expression of swallowing function in Niemann-Pick disease type C1.
    Solomon BI; Muñoz AM; Sinaii N; Farhat NM; Smith AC; Bianconi S; Dang Do A; Backman MC; Machielse L; Porter FD
    Orphanet J Rare Dis; 2022 Sep; 17(1):342. PubMed ID: 36064725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease.
    Nicoli ER; Al Eisa N; Cluzeau CV; Wassif CA; Gray J; Burkert KR; Smith DA; Morris L; Cologna SM; Peer CJ; Sissung TM; Uscatu CD; Figg WD; Pavan WJ; Vite CH; Porter FD; Platt FM
    PLoS One; 2016; 11(3):e0152007. PubMed ID: 27019000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Treatment of Niemann-Pick Type C1 Disease With Intrathecal 2-Hydroxypropyl-β-Cyclodextrin.
    Berry-Kravis E; Chin J; Hoffmann A; Winston A; Stoner R; LaGorio L; Friedmann K; Hernandez M; Ory DS; Porter FD; O'Keefe JA
    Pediatr Neurol; 2018 Mar; 80():24-34. PubMed ID: 29429782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A differential proteomics study of cerebrospinal fluid from individuals with Niemann-Pick disease, Type C1.
    Li W; Pergande MR; Crutchfield CA; Searle BC; Backlund PS; Picache JA; Burkert K; Yanjanin-Farhat NM; Blank PS; Toth CL; Wassif CA; Porter FD; Cologna SM
    Proteomics; 2023 Jun; 23(11):e2200378. PubMed ID: 36638187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracerebroventricular Treatment with 2-Hydroxypropyl-β-Cyclodextrin Decreased Cerebellar and Hepatic Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) Expression in Niemann-Pick Disease Type C Model Mice.
    Fukaura M; Ishitsuka Y; Shirakawa S; Ushihama N; Yamada Y; Kondo Y; Takeo T; Nakagata N; Motoyama K; Higashi T; Arima H; Kurauchi Y; Seki T; Katsuki H; Higaki K; Matsuo M; Irie T
    Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33466390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.